AngioDynamics (ANGO) Q1 2025: MedTech Mix Hits 41% of Revenue, Powering Margin Shift
AngioDynamics’ Q1 results show the company’s MedTech segment now comprises over 41% of total revenue, up from 38.5% last year, marking a decisive mix shift toward higher-margin platforms. This transition is supported by double-digit MedTech growth, robust adoption of Arion and AlphaVac, and ongoing manufacturing restructuring. With MedTech’s expanding share and operational catalysts in play, AngioDynamics is positioned for sustained margin improvement and long-term growth as new indications, geographies, and reimbursement pathways unlock incremental value.
Summary
- MedTech Revenue Mix Shift: Higher-margin MedTech platforms now drive over 41% of total sales, accelerating margin leverage.
- Operational Execution: AlphaVac and Arion product launches and clinical milestones fuel adoption and broaden addressable markets.
- Profitability Inflection: Outsourced manufacturing and segment mix are set to unlock $15 million in annualized savings by 2027.
Business Overview
AngioDynamics is a medical technology company focused on minimally invasive therapies for vascular and oncology applications. The company generates revenue through two primary segments: MedTech, which includes innovative platforms like Arion (atherectomy), AlphaVac (mechanical thrombectomy), and NanoKnife (IRE for oncology), and MedDevice, comprising legacy vascular access and surgical devices. MedTech growth is driven by new product launches, clinical adoption, and expanded indications, while MedDevice provides a stable, lower-growth foundation.
Performance Analysis
AngioDynamics delivered Q1 revenue of $67.5 million, up just over 1% year-over-year, with MedTech revenue rising 8.7% and now comprising 41.4% of total sales. The MedTech segment’s outperformance was led by Arion (up 24.9%) and AlphaVac (up 21.1%), offsetting softer results in NanoKnife (down 6.9%) and MedDevice (down 3.6%). The U.S. MedDevice business grew modestly, while international sales were impacted by distributor order timing, particularly for NanoKnife, which faced a tough prior-year comp from a large initial stocking order.
Gross margin came in at 54.4%, down 40 basis points year-over-year but ahead of internal expectations, reflecting positive segment mix offset by inflation and transition costs from outsourced manufacturing. The company’s adjusted EBITDA loss narrowed to $152,000, a marked improvement from last year’s $1.1 million loss, underscoring operating leverage from the shift to higher-margin platforms. Operating cash flow was negative, consistent with seasonal patterns and one-time Q1 expenses.
- MedTech Mix Leverage: The growing share of MedTech revenue is driving higher blended margins despite inflationary headwinds.
- AlphaVac and Arion Adoption: Clinical trial data and regulatory clearances are catalyzing rapid uptake, particularly in U.S. hospitals.
- Manufacturing Overhaul: Outsourcing transition is on track, with substantial margin impact expected post-completion.
Overall, AngioDynamics is executing on its strategy to pivot toward innovation-driven growth, with MedTech platforms now central to both top-line and margin expansion.
Executive Commentary
"Our MedTech segment had another strong quarter, growing approximately 9% led by Arion and AlphaVac, which both grew north of 20% in the quarter. Beyond the top line, we made significant progress towards profitability, reporting an adjusted EBITDA loss of just $200,000."
Jim Clemmer, President and Chief Executive Officer
"We expect to see gross margin accretion coming from the fact that we have a larger portion of our overall revenue base coming from that higher margin MedTech product line. We saw that this quarter. We were absolutely seeing that mix shift driving benefits in gross margin."
Steve Trowbridge, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. MedTech Platform Expansion
Arion, atherectomy device, and AlphaVac, mechanical thrombectomy system, are driving double-digit growth, supported by clinical data, new product extensions (Arion XL, 1.7mm catheter), and regulatory milestones (CE mark for Arion, full market release for AlphaVac in U.S. and Europe). These platforms are broadening AngioDynamics’ addressable market, now estimated at $10 billion, up from $3 billion three years ago.
2. Commercial and Regulatory Catalysts
New launches and regulatory wins underpin growth: The company is leveraging recent FDA and CE approvals to penetrate new hospital accounts and European markets, with initial focus on limited launches before scaling. The RECOVER-AV trial for AlphaVac in Europe and the anticipated FDA clearance for NanoKnife in prostate are set to unlock incremental growth drivers.
3. Manufacturing Transformation
Outsourced manufacturing transition is progressing as planned, targeting $15 million in annualized cost savings by fiscal 2027. This structural shift is expected to materially improve gross margins and operating leverage, though the full benefit will be realized upon program completion as overhead costs are eliminated.
4. Reimbursement and Market Access
NanoKnife’s prostate indication is advancing through FDA and reimbursement pathways, with a CPT code decision pending and FDA clearance expected by year-end. Parallel pursuit of regulatory and reimbursement milestones is designed to accelerate adoption and revenue ramp in urology.
5. Portfolio Optimization
Divestitures of lower-growth, lower-margin businesses (dialysis, PIC, RF catheters) have sharpened focus on innovation and profitability, enabling redeployment of resources to high-growth platforms and supporting the company’s pivot toward MedTech leadership.
Key Considerations
This quarter marks a clear inflection in AngioDynamics’ business model, with MedTech now the primary growth and margin driver. Investors should weigh the company’s execution against the following:
- Segment Mix Dynamics: Sustained MedTech outperformance is crucial for ongoing margin expansion and operating leverage.
- Clinical and Regulatory Execution: Timely FDA and CE approvals, along with successful clinical trials, are essential to unlock new indications and geographies.
- Manufacturing Transition Risks: While cost savings are significant, timing and execution risk remain until the transition is fully realized.
- International Order Variability: Distributor-driven international sales can create quarterly revenue choppiness, especially for NanoKnife and MedDevice.
- Cash Utilization and Profitability Path: Q1 cash burn is seasonal, but the path to cash flow positivity by FY26 depends on disciplined expense management and margin gains from mix and manufacturing.
Risks
Key risks include timing and execution challenges in outsourced manufacturing, which could delay margin improvement, and potential reimbursement setbacks for NanoKnife’s prostate indication. International distributor order timing introduces revenue volatility, and inflationary pressures may persist until cost savings are fully realized. Regulatory or clinical trial delays could also impact new product launches and adoption trajectories.
Forward Outlook
For Q2 2025, AngioDynamics guided to:
- Continued MedTech revenue growth, with easier comps for NanoKnife and expected international order recovery.
- Sequential improvement in gross margin as segment mix and cost discipline take effect.
For full-year 2025, management reiterated guidance:
- Revenue of $282 to $288 million (4.2% to 6.4% growth)
- MedTech sales up 10% to 12%, MedDevice up 1% to 3%
- Gross margin of 52% to 53%
- Adjusted EBITDA loss of $2.5 million to break-even
- Adjusted EPS loss of $0.38 to $0.42
Management emphasized MedTech mix, manufacturing savings, and regulatory milestones as the primary drivers of margin and profit inflection, with the full benefit of cost actions expected in the out-years.
- Q2 will benefit from easier comps and distributor order timing normalization.
- Cash flow expected to improve sequentially, with fiscal 2026 targeted for cash flow positivity.
Takeaways
AngioDynamics is executing a decisive pivot from legacy devices to innovation-led MedTech platforms, with segment mix and manufacturing overhaul setting the stage for margin expansion and future profitability.
- MedTech Outperformance: Double-digit growth in Arion and AlphaVac demonstrates strong product-market fit and supports the company’s strategic narrative.
- Margin Inflection in Sight: Manufacturing transition and segment mix are converging to drive sustainable operating leverage, with $15 million in annualized savings expected by 2027.
- Catalysts Ahead: FDA and reimbursement milestones for NanoKnife prostate, full commercial launches in Europe, and continued MedTech adoption will be critical watchpoints for investors.
Conclusion
AngioDynamics’ Q1 results highlight a business in transition, with MedTech platforms now central to growth and profitability. Execution on regulatory, commercial, and operational fronts will determine whether the company can fully realize its margin and cash flow ambitions in the coming quarters.
Industry Read-Through
AngioDynamics’ results reinforce a broader medtech trend: platform innovation, clinical data, and targeted portfolio focus are essential to drive growth and margin expansion in a mature device market. The success of Arion and AlphaVac underscores the value of new indication expansion and physician-centric design, while the shift to outsourced manufacturing reflects industry-wide cost discipline. For peers, the interplay between regulatory milestones, reimbursement clarity, and operational execution will increasingly separate winners from laggards as the sector pivots toward higher-margin, innovation-driven portfolios.